Background: Irreversible hearing loss is a well-known adverse effect of aminoglycosides, however, inability to accurately predict ototoxicity is a major limitation in clinical care. We addressed this ...

Achieved Third Quarter 2024 Net Product Sales of $7.0 Million ~~ Increasing Momentum and Successful Reimbursement in the Adolescent and Young ...

Dizziness is a common and bothersome symptom of many different medical conditions. It is usually not a cause for serious ...

Fennec Pharmaceuticals ( (FENC) ) has released its Q3 earnings. Here is a breakdown of the information Fennec Pharmaceuticals presented to its ...

Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced ...

Good afternoon, and welcome to the MannKind Corporation third quarter 2024 financial results earnings call. As a reminder, ...

Walker & Dunlop, Inc. (the "Company," or "Walker & Dunlop") reported quarterly total transaction volume of $11.6 billion, up 36% from the third quarter of 2023, which drove total revenues of $292.3 ...

Summit is being held from Wednesday to Thursday in Kunming, Southwest China's Yunnan Province. The leaders of China and the other five Mekong countries, including Cambodia, Laos, Myanmar, Thailand ...

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing ...

Abstract and Introduction Empirical Antimicrobial Therapy Against Gram-negative Pathogens Adverse Consequences Related to Combination Antimicrobial Use Conclusion References A recent retrospective ...

Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ETCompany ParticipantsMichael Castagna - CEOChris Prentiss ...